机构:[1]Wuhan Childrens Hosp, Wuhan, Peoples R China;[2]Huazhong Univ Sci & Technol, Wuhan, Peoples R China;[3]Wuhan Inst Virol, Wuhan, Peoples R China;[4]Beijing Childrens Hosp, Beijing, Peoples R China;首都医科大学附属北京儿童医院[5]Univ Calif Davis, Davis, CA 95616 USA;[6]Chinese Natl Clin Res Ctr Resp Dis, Beijing, Peoples R China;[7]Inst Maternal & Child Hlth, Wuhan, Peoples R China;[8]Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
To the Editor: Discordant results from the Treatment of Uncontrolled Lupus via the Interferon Pathway (TULIP)-1 trial(1) and the TULIP-2 trial (Jan. 16 issue)(2) have stimulated discussion about whether the British Isles Lupus Assessment Group-based Combined Lupus Assessment, the Systemic Lupus Erythematosus Responder Index, or some combination thereof accurately measures response in patients with active systemic lupus erythematosus (SLE).(3,4) Few practicing clinicians could name the components of either assessment, and in my experience, fewer still have ever used them. A simple, clinically meaningful question such as "Do you feel better?" could clarify this debate. Both trials evaluated multiple patient-reported outcome . . .
第一作者机构:[1]Wuhan Childrens Hosp, Wuhan, Peoples R China;
通讯作者:
通讯机构:[1]Wuhan Childrens Hosp, Wuhan, Peoples R China;[8]Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
推荐引用方式(GB/T 7714):
Lu Xiaoxia,Zhang Liqiong,Du Hui,et al.Anifrolumab in Systemic Lupus Erythematosus[J].NEW ENGLAND JOURNAL OF MEDICINE.2020,382(17):1665-1666.doi:10.1056/NEJMc2002191.
APA:
Lu, Xiaoxia,Zhang, Liqiong,Du, Hui,Zhang, Jingjing,Li, Yuan Y....&Wong, Gary W. K..(2020).Anifrolumab in Systemic Lupus Erythematosus.NEW ENGLAND JOURNAL OF MEDICINE,382,(17)
MLA:
Lu, Xiaoxia,et al."Anifrolumab in Systemic Lupus Erythematosus".NEW ENGLAND JOURNAL OF MEDICINE 382..17(2020):1665-1666